Hydrogel for treating oral submucosal fibrosis as well as preparation method and application thereof
The intelligent release of the drug is achieved by applying a potable hydrogel composed of tanshinone IIA modified particles, four-arm polyethylene glycol norbornene hydrogel and MMP-9 specific polypeptide at the fibrous lesion site under the oral mucosa. and long-term local effects have solved the problems of poor efficacy, large side effects and inconvenient administration in the prior art, and improved the therapeutic effect and economical benefits.
Patent Information
- Application Number
- CN202411146200.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-29
AI Technical Summary
The prior art has poor efficacy in treating submucosal fibrous changes, has large side effects, is complicated to operate, is expensive, and is inconvenient to do so, making it difficult to last for a long time, resulting in discomfort and increased economic burden during the treatment process.
A potable hydrogel consisting of tanshinone IIA modified particles, four-arm polyethylene glycol norbornene hydrogel, MMP-9 specific polypeptide and photoinitiator is used to form a network structure through ultraviolet irradiation to achieve intelligent drug release and long-term local effects.
The hydrogel has a stable network structure, strong elasticity and viscosity, and can act continuously in the oral environment for a long time, reduce patient discomfort, reduce treatment costs, improve treatment effects, and has the potential to promote oral mucosal repair.
Smart Images

Figure CN119033677A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of oral mucosal disease treatment materials and relates to a hydrogel for treating oral submucosal fibrosis and a preparation method and application thereof. Background Art
[0002] Oral submucous fibrosis (OSF) is a chronic, insidious, progressive oral mucosal disease characterized by epithelial atrophy, extensive collagen fiber deposition in connective tissue, and increased myofibroblasts. It is one of the main precancerous states of oral squamous cell carcinoma. There are approximately 5 million OSF patients worldwide. The disease is more common in India, Southeast Asian countries and regions, and southern China, while the incidence is lower in Europe, the United States, and Japan. This is closely related to OSF-related risk factors such as chewing betel nut, smoking, drinking, and eating spicy foods. The malignant transformation rate of OSF is high, about 7% to 15%. Therefore, it is particularly necessary to block or delay the progression of the disease in the early stage of OSF cancer. In clinical staging, OSF is manifested by vascular congestion and inflammation in the early stage; vascular reduction and fibrosis in the middle stage, and whitening of the oral mucosa; vascular occlusion in the late stage, fibrous strips appear in the oral mucosa, and the patient's mouth is significantly limited. Its histopathological basis is the morphological changes of oral mucosal epithelial cells and epithelial spikes and the deposition of dense collagen cords under the epithelium. These clinical manifestations and pathological basis can be used as one of the diagnostic bases for OSF. Due to its complex pathogenesis and difficult treatment, most cases choose conservative treatment.
[0003] The difficulties in treating OSF are as follows: 1. The surgery is traumatic, expensive, and prone to scar tissue formation. Once oral submucous fibrosis enters the late stage, it will affect a large area of oral and maxillofacial tissue, causing stiff buccal mucosal tissue, facial deformation, swelling, difficulty opening the mouth, and even affecting breathing and swallowing. In order to remove the diseased tissue, most of the soft tissue in the oral cavity must be removed, even including the tongue tissue. OSF patients have their appearance affected, and are usually reluctant to go out to socialize, and are prone to inferiority and suicidal psychology. In addition, since most of the oral and maxillofacial tissues are removed, eating and speech functions are affected, which brings many inconveniences to the patient's life. This type of surgery is complicated, and the cost of surgical rehabilitation and convalescence is expensive, which brings a heavy economic and psychological burden to the patient and his family, and is also a serious social public health issue. 2. The effect of drug treatment is not ideal, there are many side effects, and it is easy to relapse. There is no clear standard for the recommended drugs and treatment plans for oral submucous fibrosis. Glucocorticoids, such as the medium-acting glucocorticoid triamcinolone acetonide and the long-acting glucocorticoid betamethasone, which are commonly used in Western medicine, can achieve good results in the short term, but the side effects are very obvious, and they often need to be used in combination with traditional Chinese medicine. Photodynamic therapy is easy to operate and has a quick effect, but it is expensive and prone to recurrence, so it is generally not recommended. Traditional Chinese medicine is cheap and has few side effects, but the currently commonly used natural medicines such as curcumin, salvia miltiorrhiza, and aloe have poor therapeutic effects. Therefore, it is necessary to find emerging potential strong anti-fibrosis therapeutic drugs as an alternative for clinical treatment. 3. OSF has a single dosage form, low administration efficiency, and short duration of action. The commonly used dosage forms for OSF treatment are oral and injection, and the drug utilization efficiency is not high. Oral administration will reduce the bioavailability due to the first-pass effect of the liver, thereby reducing the efficacy. Local application is difficult to act for a long time because the drug stays in the mouth for a short time. Although injection treatment can directly touch the lesion, the pain it brings greatly reduces the patient's clinical compliance. Hydrogel is an emerging advantageous drug-carrying material that can adapt to the complex environment of the oral cavity and is widely used in the treatment of various oral diseases. However, there are few reports and applications in the treatment of OSF, and there is a lack of relevant experimental data and clinical translational applications.
[0004] At present, there are related studies, such as Chinese patent application number CN202010345200.6 for oral submucosal fibrosis dressings and their preparation and application. This invention belongs to the technical field of topical oral cancer treatment materials, and specifically relates to a hydrogel medical dressing for relieving oral submucosal fibrosis, one of the precancerous lesions of oral cancer, which is an alginate / acrylic acid / montmorillonite composite hydrogel with chemically cross-linked cesium ions. In addition, the invention also provides a preparation method and application of the hydrogel. The composite hydrogel described in the invention innovatively adds cesium ions to the alginate / acrylic acid / montmorillonite composite hydrogel to regulate its cell protection effect after arecoline damage, which can reduce the inflammatory response of oral epithelial cells, increase the secretion of oral mucosal adhesion proteins to build an epithelial barrier, regulate the disordered state of collagen, prevent further damage from arecoline, and prevent further damage from arecoline, thereby preventing OSF from deteriorating into oral cancer and achieving the purpose of prevention.
[0005] Another example is Chinese patent application number CN201310042448.5, a multi-component synchronous balanced drug release long-acting preparation containing effective ingredients of salvia miltiorrhiza and panax notoginseng. The invention discloses a multi-component synchronous balanced drug release long-acting preparation containing effective ingredients of salvia miltiorrhiza and panax notoginseng, which belongs to the field of traditional Chinese medicine and pharmaceutical preparation. The preparation is composed of nine parts, including a salvia miltiorrhiza total phenolic acid rapid release unit, a salvia miltiorrhiza total phenolic acid medium-acting sustained release unit, a salvia miltiorrhiza total phenolic acid long-acting sustained release unit, a total tanshinone rapid release unit, a total tanshinone enteric-coated unit, a total tanshinone long-acting sustained release unit, a panax notoginseng total saponin rapid release unit, a panax notoginseng total saponin enteric-coated unit, and a panax notoginseng total saponin long-acting sustained release unit. The drug can be used to treat cardiovascular and cerebrovascular diseases, and the drug can be continuously released for 12 hours.
[0006] At present, there are still some deficiencies in the existing technology: 1. Treatment defects: The current treatment methods for OSF are mainly divided into surgical treatment, drug treatment and physical therapy, most of which are conservative treatments. Surgical treatment includes excision of fibrous bands, skin grafting, etc., which can only improve the patient's difficulty in opening the mouth to a certain extent, are prone to recurrence, and are difficult to be accepted by patients due to risks such as scar contracture. Therefore, drug treatment is often the first choice. Drug treatment is divided into Western medicine treatment and Chinese medicine treatment. In China, Danshen combined with glucocorticoids is widely used in the clinical treatment of OSF, but glucocorticoids cannot reverse the abnormal deposition of fibrous tissue and restore the elasticity of the oral mucosa. Excessive or inappropriate application will produce adverse reactions and glucocorticoid resistance, and have high recurrence and strong side effects. Simple Danshen injection can often only change the degree of mouth opening limitation of OSF patients, but the effect of relieving the patient's mucosal burning pain symptoms is poor. 2. Insufficient treatment methods: The surgery is traumatic and expensive, which causes the patient's appearance to be damaged to a certain extent, affecting the patient's social and mental health. In the traditional method of administration, injection treatment causes pain, patient compliance is not high, and can only be operated by medical staff, and patients cannot take medicine at home by themselves. Oral administration reduces the utilization rate of drugs due to the first-pass effect of the liver. Buccal administration has a higher utilization rate than oral administration, but the drug dissolves in saliva, which may cause the loss of drug components, and there are fewer drugs that can continue to act locally on the oral mucosa. Atomized administration can fully diffuse to the mucosal surface, but the action time is short. Summary of the invention
[0007] In view of the shortcomings of the prior art in the treatment of oral submucous fibrosis, such as poor efficacy, large side effects, cumbersome operation and high price, the present invention provides a hydrogel for the treatment of oral submucous fibrosis and its preparation method and application. The purpose of the present invention is to provide a new drug option for the clinical treatment of OSF and to improve the dosage form so that it can effectively and continuously act on the lesion, thereby reducing the discomfort and economic burden of patients during the treatment process. It is expected to become a preferred solution widely used in clinical treatment.
[0008] The technical solution of the present invention is as follows:
[0009] Take 0.2g of Tanshinone ⅡA (TanⅡA) and dissolve it in 20ml of anhydrous ethanol, evenly disperse 2g of pregelatinized starch, heat in a water bath to volatilize the solvent, and make TanⅡA modified particles to increase the water solubility of the drug particles. Take 1g of Panax notoginseng total saponins (PNS), dissolve it in ultrapure water and mix it evenly, freeze-dry the resulting solution, grind it through an 80-mesh sieve, and make PNS-TanⅡA composite particles;
[0010] Then, four-arm polyethylene glycol norbornene (4-arm PEG-a-NB) was used as the basic network framework of the hydrogel, combined with matrix metalloproteinase 9 (MMP-9) specific peptide as a connecting network bridge, to intelligently respond to the abnormally elevated MMP-9 in the oral cavity of OSF patients, and at the same time, a photoinitiator phenyl-2,4,6-trimethylbenzoylphosphinate lithium (LAP) was introduced to promote the connection between the two. The above reactions were all carried out using PBS solution as a solvent to complete the preparation of the hydrogel precursor solution;
[0011] Subsequently, the PNS-TanⅡA composite particles were evenly mixed with the hydrogel precursor solution (1 mg: 100 μL) to complete the hydrogel drug loading. The drug-loaded hydrogel precursor solution was irradiated with a 365 nm ultraviolet lamp at a distance of about 1 cm for 30 seconds to complete the preparation of the drug-loaded hydrogel.
[0012] The following are the technical principles of the present invention:
[0013] 1. Modification principle of Tanshinone ⅡA:
[0014] The solvent deposition method is used to modify the lipophilic tanshinone ⅡA into a hydrophilic one. The drug is assembled into a solid dispersion (a solid dispersion is a group of solid products composed of at least two different components, namely a hydrophilic matrix and a lipophilic drug, and the drug can be dispersed into amorphous particles or crystalline particles), thereby improving the solubility of the poorly water-soluble drug in the pharmaceutical composition, accelerating the dissolution rate, and improving the bioavailability of the drug.
[0015] 2. Principle of hydrogel photocuring:
[0016] Hydrogel photocuring is a process that uses ultraviolet light (UV) to irradiate a hydrogel precursor (prepolymer) to rapidly solidify it into a solid state. A photoinitiator is a class of compounds that can absorb light of a specific wavelength and convert it into a chemically active substance. After adding an appropriate amount of photoinitiator to the hydrogel material, when the material is exposed to ultraviolet light, the photoinitiator absorbs light energy and converts it into an active substance that can cause a chemical reaction in the hydrogel. These active substances trigger a chain reaction, thereby cross-linking the monomer molecules in the hydrogel to form a three-dimensional network structure, thereby solidifying the hydrogel. The photoinitiator LAP used in this gel is a water-soluble, cell-compatible type I photoinitiator, which is commonly used in the polymerization of hydrogels or other polymer materials. It has a faster polymerization rate under 365nm ultraviolet light, so a 365nm ultraviolet lamp is selected to irradiate the hydrogel precursor.
[0017] 3. Working principle of hydrogel MMP-9 (matrix metalloproteinase 9) specific peptide:
[0018] In normal tissues, MMP-9 is less expressed or not expressed, and the drug is not released. In pathological tissues, that is, OSF tissues, MMP-9 is expressed at a higher level, and the MMP-9 specific polypeptide in the hydrogel controls the drug release for the treatment of OSF.
[0019] Matrix metalloproteinases (MMPs) are a family of endopeptidases that mainly degrade collagen fibers and are widely expressed in a variety of cells. Under physiological conditions, the activity and expression of MMPs are strictly regulated by specific inhibitors, cytokines, hormones, and cell-cell interactions. However, under pathological conditions, such as inflammation and fibrotic diseases, the regulatory function of MMPs is abnormal, resulting in highly upregulated activity. MMP-9 is a gelatinase that can hydrolyze denatured collagen and type IV collagen, the main component of the basement membrane, and plays a key role in a variety of pathological processes. MMP-9 is mostly negatively expressed in normal buccal mucosa, while MMP-9 expression is upregulated in the early stage of OSF, indicating that high expression of MMP-9 can confirm the early onset of OSF.
[0020] The hydrogel MMP-9 specific polypeptide (purity>95%, purchased from Hangzhou Zhuanpeptide Biotechnology Co., Ltd.) can specifically respond to MMP-9. Its design is based on the site-specific analysis of MMPs. By placing leucine in P1', glycine in P3', and proline in P3, a double cysteine peptide linker optimized for MMP-9 cleavage is designed, which optimizes the performance of insufficient cross-linking efficiency, MMP-9 sensitivity and low specificity in a hydrated environment.
[0021]
[0022] Customized MMP-9 sensitive peptide linker (CGPGG↓LAGGC)
[0023] 4. Principle of hydrogel network cross-linking:
[0024] Using 4-arm PEG-a-NB as the MMP-9 hydrogel scaffold, the thiol group on the MMP-9 specific polypeptide was photopolymerized with the norbornene in the 4-arm PEG-a-NB polymer to cross-link the polypeptide with the branched 4-arm PEG to form a hydrogel network. The degree of cross-linking of the thiol-norbornene ladder growth photopolymerization was almost complete.
[0025] The purpose of the present invention is achieved through the following technical solutions:
[0026] A method for preparing a hydrogel for treating oral submucous fibrosis comprises the following steps:
[0027] S1 Preparation of Panax notoginseng total saponins-tanshinone ⅡA aqueous solution:
[0028] S1.1 Modification of Tanshinone ⅡA by solvent deposition method:
[0029] S1.1.1 Dissolve 0.2 g of Tanshinone ⅡA powder in 20 ml of anhydrous ethanol;
[0030] S1.1.2 Disperse 2 g of pregelatinized starch (PGS) into the solution and stir at a constant speed in a water bath at 40-50°C until the solution is completely evaporated;
[0031] S1.1.3 Place the product in a constant temperature drying oven and dry it to constant weight;
[0032] S1.1.4 Grind the material until it can all pass through an 80-mesh sieve to obtain tanshinone ⅡA modified particles;
[0033] S1.1.5 Cover with tin foil and seal in a refrigerator for later use, and keep away from light;
[0034] S1.2 Preparation of freeze-dried precursor solution:
[0035] Dissolve 1 g of Panax notoginseng total saponins and the above-mentioned tanshinone ⅡA modified particles in a small beaker with ultrapure water to prepare a lyophilized precursor solution;
[0036] S2 Pretreatment of freeze-dried samples (freezing stage):
[0037] S2.1 Pour the freeze-dried precursor solution into the tray, the solution height is about 1mm;
[0038] S2.2 Use sealing film to seal the opening of the pallet;
[0039] S2.3 Place the tray containing the lyophilized precursor solution into an ultra-low temperature freezer at -80°C for 4 to 12 hours;
[0040] Use of S3 freeze dryer (sublimation drying stage):
[0041] S3.1 Turn on the power of the drying chamber and wait for 20-30 minutes until the temperature indicator reaches -40℃ before starting the operation;
[0042] S3.2 Take out the sample obtained in S2 from the ultra-low temperature freezer and use a sharp object to poke a small hole in the sealing film;
[0043] S3.3 Place it in the drying chamber and close the valve connecting the drying chamber to the atmosphere to ensure good air tightness;
[0044] S3.4 First check the oil level of the vacuum pump, connect the power supply after confirming it is normal (if the oil level is abnormal, adjust the vacuum pump pressure), then open the valve behind the drying chamber to connect it to the vacuum pump, and finally start the vacuum pump, wait for 20-30 minutes, observe the changes of the sample, and after confirming that there is no bumping phenomenon, continue to fully dry in the drying chamber for 12 hours;
[0045] S4 Dehydration and storage of dried samples (dehydration stage):
[0046] S4.1 Close the valve connected to the vacuum pump at the back of the drying chamber, turn off the vacuum pump, and unplug the power supply of the vacuum pump;
[0047] S4.2 Loosen the air valve to restore the air pressure in the drying chamber to the same as the atmospheric pressure;
[0048] S4.3 Turn off the power to the freezer, unplug the power socket, and remove the plexiglass cover;
[0049] S4.4 After taking out the dried sample, quickly cover it with a layer of sealing film and tie it tightly with a thin thread (to prevent the sample from absorbing moisture);
[0050] S4.5 Clean and organize the equipment;
[0051] S5 Preparation of PBS solution containing photoinitiator LAP:
[0052] S5.1 Place a 15 ml beaker on an electronic scale, place a 15 ml centrifuge tube in the beaker, and zero the electronic scale;
[0053] S5.2 Use a 100-1000 μl pipette to draw 10 ml of PBS phosphate buffer into a 15 ml centrifuge tube. The density of PBS phosphate buffer is 1 g / ml, and the electronic scale reading is 10 g;
[0054] S5.3 Calculate the amount of LAP required to prepare 10 ml of PBS phosphate buffer with a concentration of 0.05 wt% (w / w, i.e., mass of solute / mass of solution) LAP: 5 mg (the mass of LAP differs from that of PBS by more than two orders of magnitude, so the mass of LAP is negligible);
[0055] S5.4 Weigh 5 mg of LAP using an analytical balance and add it to a 15 ml centrifuge tube filled with PBS phosphate buffer. Set the oscillator to automatic mode (mode B) and the speed to 800 rpm. Place the 15 ml centrifuge tube on the oscillator and oscillate for 5 minutes to obtain 10 ml of PBS phosphate buffer with a concentration of 0.05 wt% LAP. Wrap the centrifuge tube with tin foil and place it in a foam paper box containing an ice pack for later use (to prevent the photoinitiator from being inactivated by external light and temperature).
[0056] S6: Prepare PBS solution containing PEG polymer and PBS solution containing MMP-9 specific peptide:
[0057] S6.1 Use an analytical balance to weigh 50 mg of 4-arm-PEG-NB polymer powder and 7.93 mg of customized MMP-9 specific peptide powder, and place them in 1.5 ml semi-cylindrical bottom EP tubes respectively (keep the concentration of 4-arm PEG-a-NB polymer in the precursor solution at 10 wt %, and keep the ratio of olefin bonds on the 4-arm PEG-a-NB polymer to thiol on the MMP-9 specific peptide at 1:1);
[0058] S6.2 Use a 100-1000 μl and 10-100 μl pipette to draw 342 μl of the PBS phosphate buffer with a concentration of 0.05 wt% LAP prepared in step 1 and add it to the EP tube containing the 4-arm PEG-a-NB polymer powder and mix well;
[0059] S6.3 Use a 100-1000 μl pipette to draw 100 μl of the PBS phosphate buffer with a concentration of 0.05 wt% LAP prepared in step 1 and add it to the EP tube containing the customized MMP-9 specific polypeptide powder and mix well;
[0060] S6.4 Adjust the oscillator to the automatic mode (B mode), set the speed to 800 rpm, place the two tubes of solution on the oscillator and oscillate for 5 minutes to obtain a PBS solution containing a 4-arm PEG-a-NB polymer and a PBS solution containing a MMP-9 specific polypeptide;
[0061] S7 Preparation of MMP-9 enzyme responsive hydrogel precursor solution:
[0062] S7.1 Use a 100-1000 μl pipette to pipette the PBS solution containing the 4-arm PEG-a-NB polymer prepared in step 2 into the semi-cylindrical bottom EP tube containing the PBS solution of the MMP-9 specific polypeptide and mix well;
[0063] S7.2: Adjust the oscillator to the automatic mode (mode B), set the speed to 800 rpm, place the EP tube on the oscillator and oscillate for 5 minutes to obtain 442 μl of MMP-9 enzyme-responsive hydrogel precursor solution;
[0064] S8 Preparation of drug-loaded hydrogel precursor solution:
[0065] S8.1 Dissolve PNS-TanⅡA in gel precursor solution, and ensure that the ratio of PNS-TanⅡA: gel precursor solution is 1 mg: 100 μl;
[0066] S9 UV light curing MMP-9 enzyme response hydrogel precursor solution, storage:
[0067] S9.1 Use a 365 nm ultraviolet lamp to irradiate the MMP-9 enzyme-responsive hydrogel precursor solution at a distance of 1 cm for 30 seconds to photocurate the MMP-9 enzyme-responsive drug-loaded hydrogel;
[0068] S9.2 Place the solidified MMP-9 enzyme-responsive drug-loaded hydrogel in a drying container for low-temperature storage.
[0069] Furthermore, S2.2 uses sealing film to seal the tray mouth in order to ensure sufficient freezing, prevent the sample aqueous solution from boiling in the vacuum environment of the drying chamber, and avoid contamination between different samples.
[0070] Furthermore, in S3.2, a sharp object is used to poke a small hole in the sealing film, in order to facilitate the escape of sublimated water vapor from the sample system.
[0071] Furthermore, S3.3 ensures good airtightness in order to prepare for creating a vacuum environment.
[0072] Furthermore, after S3.4 confirms that there is no violent boiling, the purpose is to reflect that the sample is completely frozen. Vibrating boiling indicates that the sample is not completely frozen.
[0073] Furthermore, in S4.2, the valve should be loosened slowly and carefully at first so that no "hissing" sound of airflow can be heard, to prevent excessive airflow from entering and blowing away the sample.
[0074] Furthermore, in S5.4, tin foil is used to wrap the centrifuge tube and placed in a foam paper box containing an ice pack for standby use, in order to prevent the photoinitiator from being inactivated by external light and temperature.
[0075] Furthermore, an analytical balance was used in S6.1 to weigh 50 mg of 4-arm PEG-a-NB polymer powder and 7.93 mg of customized MMP-9 specific polypeptide powder, with the aim of maintaining the concentration of the 4-arm PEG-a-NB polymer in the precursor solution at 10 wt % and maintaining the ratio of olefin bonds on the 4-arm PEG-a-NB polymer to thiol bonds on the MMP-9 specific polypeptide at 1:1.
[0076] A hydrogel for treating oral submucous fibrosis is obtained by using the above-mentioned method for preparing a hydrogel for treating oral submucous fibrosis. The hydrogel has the following technical indicators:
[0077] Hydrogel performance characterization: ① Hydrogel appearance: colorless and transparent, crystalline and frozen, a classic gel morphology;
[0078] ② Infrared spectroscopy characterization of hydrogel: Compared with four-arm PEG-a-NB, the out-of-plane bending vibration of olefin CH (1000-675cm -1 ) and in-plane bending vibration (1430-1290cm -1 ) is significantly weakened, and the C=C characteristic stretch (1680-1640cm -1 ) disappears, a gel network is formed through double bond reaction, and the gel is successfully cross-linked;
[0079] ③Scanning electron microscopy characterization of hydrogel: The hydrogel has a porous and interconnected microstructure, and its morphology is similar to that of regenerated extracellular matrix;
[0080] ④ Rheological properties: hydrogel has a stable network structure, strong elasticity and certain viscosity;
[0081] ⑤ In vitro swelling performance: The equilibrium swelling rate of the hydrogel is 300%, which is suitable for the highly humid environment of the oral cavity.
[0082] The present invention also relates to the use of the above-mentioned hydrogel for treating oral submucous fibrosis, and is used for preparing a pharmaceutical composition for treating oral submucous fibrosis.
[0083] Compared with the prior art, the present invention has the following advantages:
[0084] 1. The hydrogel for treating oral submucosal fibrosis of the present invention has a stable network structure, strong elasticity and certain viscosity. It has high swelling performance and can meet the requirements of not deforming and falling off in a dynamic oral moist environment for a long time. The hydrogel medical dressing of the present invention has safe and non-toxic ingredients and has good application prospects.
[0085] 2. The method for preparing a hydrogel for treating oral submucosal fibrosis described in the present invention innovatively uses MMP-9 specific polypeptide as a target for drug release in advance, and uses the photopolymerization reaction of thiol-norbornene to cross-link the polypeptide with the branched 4-arm PEG to form a hydrogel network. The starch-modified composite particles are modified into the gel to successfully prepare a specific enzyme-responsive hydrogel dressing loaded with PNS-TanⅡA composite particles. The MMP-9-cut optimized bicysteine polypeptide optimizes the performance of insufficient cross-linking efficiency, low MMP-9 sensitivity and specificity in a hydrated environment. It can also regulate the release of PNS-TanⅡA and improve the effect of hydrogel in treating OSF.
[0086] 3. The use of a hydrogel for treating oral submucosal fibrosis according to the present invention, the hydrogel prepared by the preparation method has the potential to promote oral mucosal repair. In the present invention, the hydrogel of the present invention is directly applied to the lesion site of OSF, and through the combined action of the various components in the hydrogel, an innovative hydrogel of traditional Chinese medicine composite particles for treating OSF and preventing oral cancer is provided. BRIEF DESCRIPTION OF THE DRAWINGS
[0087] The accompanying drawings are used to provide further understanding of the present invention and constitute a part of the specification. They are used to explain the present invention together with the embodiments of the present invention and do not constitute a limitation of the present invention.
[0088] Figure 1The appearance of the PNS-TanⅡA composite particle powder and the technical roadmap for constructing the MMP9 enzyme-responsive hydrogel in the embodiments of the present invention ((A) the appearance of the PNS-TanⅡA composite particle powder; (B) the technical roadmap for constructing the MMP-9 enzyme-responsive hydrogel);
[0089] Figure 2 This is a graph showing the particle size test and analysis of the composite particles in the embodiment of the present invention;
[0090] Figure 3 This is an appearance diagram of a successfully prepared hydrogel matrix in an embodiment of the present invention;
[0091] Figure 4 This is an infrared spectrum of the hydrogel in the embodiment of the present invention;
[0092] Figure 5 This is a scanning electron microscope image of the hydrogel in the embodiment of the present invention;
[0093] Figure 6 This is a graph showing the rheological properties of the hydrogel in an embodiment of the present invention;
[0094] Figure 7 This is a diagram of the swelling performance of the hydrogel in the embodiment of the present invention;
[0095] Figure 8 This is a flow chart of the preparation of PNS-TanⅡA hydrogel in an embodiment of the present invention;
[0096] Fig. 9 This is a schematic diagram of the principle of controlled release of drugs by hydrogel in an embodiment of the present invention;
[0097] Fig.10 This is a schematic diagram of the hydrogel network cross-linking principle in an embodiment of the present invention. DETAILED DESCRIPTION
[0098] The following examples are provided to facilitate a better understanding of the present invention, but are not intended to limit the present invention. The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are purchased from conventional biochemical reagent companies unless otherwise specified. The quantitative tests in the following examples are all repeated three times.
[0099] Example:
[0100] A preparation method of a hydrogel dressing for treating oral submucosal fibrosis:
[0101] 1. Preparation of Composite Particles
[0102] (I) Preparation of Panax notoginseng saponins-tanshinone ⅡA aqueous solution
[0103] ① Modification of Tanshinone ⅡA by solvent deposition method:
[0104] (1) Dissolve 0.2 g of Tanshinone ⅡA powder in 20 ml of anhydrous ethanol;
[0105] (2) Disperse 2 g of PGS into the solution and stir at a constant speed in a water bath at 40-50 °C until the solution is completely evaporated;
[0106] (3) Dry the product in a constant temperature drying oven until constant weight;
[0107] (4) Grinding the material until it can all pass through an 80-mesh sieve;
[0108] (5) Cover with tin foil and place in the refrigerator for later use, away from light.
[0109] ②Prepare freeze-dried precursor solution:
[0110] Dissolve 1 g of Panax notoginseng total saponins and the above-mentioned tanshinone ⅡA modified particles in a small beaker with ultrapure water to prepare a freeze-dried precursor solution.
[0111] (II) Pretreatment of freeze-dried samples (freezing stage)
[0112] ① Pour the sample aqueous solution into the tray (solution height is about 1mm).
[0113] ② Use sealing film to seal the tray mouth (to ensure sufficient freezing, prevent the sample aqueous solution from boiling violently in the vacuum environment of the drying chamber, and avoid contamination between different samples).
[0114] ③ Place the tray containing the sample solution in an ultra-low temperature refrigerator and freeze it overnight (-80℃ for 4h to 12h).
[0115] (III) Use of freeze dryer (sublimation drying stage)
[0116] ① Turn on the power of the drying chamber and wait for 20-30 minutes until the temperature indicator reaches about -40℃ before starting the operation.
[0117] ② Take out the sample from the ultra-low temperature freezer and use a sharp object to poke a small hole in the sealing film (to facilitate the sublimation of water vapor from the sample system).
[0118] ③Put it into the drying chamber, close the valve connecting the drying chamber to the atmosphere, and ensure good air tightness (prepare to create a vacuum environment).
[0119] ④ First check the oil level of the vacuum pump, connect the power supply after confirming it is normal (if the oil level is abnormal, adjust the vacuum pump pressure), then open the valve behind the drying chamber to connect it to the vacuum pump, and finally start the vacuum pump, wait for 20-30 minutes, observe the changes in the sample, and confirm that there is no bumping phenomenon (reflecting that the sample is completely frozen, bumping means that the sample is not completely frozen), and continue to fully dry in the drying room for about 12 hours.
[0120] (IV) Storage and access of samples after dehydration and drying (dehydration stage)
[0121] ① Close the valve connected to the vacuum pump at the back of the drying chamber, turn off the vacuum pump, and unplug the power supply of the vacuum pump.
[0122] ② Slowly loosen the air valve to restore the air pressure in the drying chamber to the same as the atmosphere. (When loosening the valve at first, it is necessary to loosen it slowly and carefully, so that no "hissing" sound of airflow can be heard, to prevent excessive airflow from entering and blowing away the sample).
[0123] ③ Turn off the power of the freezer, unplug the power socket, and remove the plexiglass cover.
[0124] ④ After taking out the dried sample, quickly cover it with a layer of sealing film and tie it tightly with a thin thread (to prevent the sample from absorbing moisture).
[0125] ⑤Clean and organize the instruments.
[0126] 1.4 Experimental results:
[0127] like Figure 1 As shown, the dry composite particles were successfully prepared, and there were no obvious impurities observed by naked eyes. There was no container adhesion during sieving and bagging, and the particles accumulated in the form of dry powder. The finished product had a fine granular appearance, uniform texture, and uniform bright red color.
[0128] Figure 1 A Appearance of PNS-TanⅡA composite particle powder;
[0129] 2. Preparation of Hydrogel Matrix
[0130] 2.1 Material selection:
[0131] ① The photoinitiator LAP has mild photopolymerization reaction conditions and has a spatiotemporal control effect on the material formation. It can be used for 365nm-405nm water-based UV-LED curing. Compared with the photoinitiator Irgacure 2959, LAP has a low concentration, high efficiency in trace amounts, and a short curing time. In the cell activity test under the same conditions, LAP has better biocompatibility than Irgacure 2959. Therefore, LAP was selected as the photoinitiator in this experiment.
[0132] ② Polyethylene glycol (PEG) can be used as a framework for hydrogels due to its excellent controllable material properties (such as elasticity and degradability). Norbornene (NB) is a bridged cyclic hydrocarbon composed of cyclohexene and a methylene bridge (between C-1 and C-4), and its double bond causes significant ring strain and reactivity. Compared with traditional ester-functionalized NB, amide-functionalized NB has higher hydrolytic stability. PEG-based alkenyl derivatives 4-arm PEG-a-NB can avoid the challenges brought by random chain polymerization while retaining the advantages of click photochemistry. Therefore, amide-functionalized 4-arm PEG-a-NB polymer (10kDa, purchased from Huateng Pharmaceutical Co., Ltd.) was used in this experiment.
[0133] 2.2 Experimental Procedure
[0134] The hydrogel was synthesized using the thiol-norbornene reaction: 50 mg of 4-arm PEG-a-NB polymer powder and 7.93 mg of customized MMP-9 specific polypeptide powder (keeping the ratio of olefin bonds on the 4-arm PEG-a-NB polymer to thiols on the MMP-9 specific polypeptide at 1:1) were weighed using an analytical balance and dissolved in PBS containing 0.05 wt% LAP, respectively. The mixture was vortexed at 800 rpm for 5 min to obtain a precursor solution formula with a polymer concentration of 10 wt%, and the ratio of olefin bonds on the 4-arm PEG-a-NB polymer to thiols on the MMP-9 specific polypeptide was 1:1. The precursor solution was then irradiated with a 365 nm ultraviolet lamp at a distance of 1 cm for 30 s, and the uncross-linked MMP-9 enzyme-responsive hydrogel was photocured into a hydrogel matrix.
[0135] Figure 1 B Flowchart of the construction of MMP-9 enzyme-responsive hydrogel;
[0136] 2.3 Specific experimental steps:
[0137] (I) Preparation of PBS solution containing photoinitiator LAP:
[0138] ① Place a 15ml beaker on the electronic scale, place a 15ml centrifuge tube in the beaker, and adjust the electronic scale to zero;
[0139] ② Use a 100-1000μl pipette to draw 10ml PBS phosphate buffer into a 15ml centrifuge tube, and the electronic scale reads 10g (the density of PBS phosphate buffer is 1g / ml);
[0140] ③ Calculate the amount of LAP required to prepare 10 ml of PBS phosphate buffer solution with a concentration of 0.05% (w / w, i.e., solute mass / solution mass) of phenyl-2,4,6-trimethylbenzoyl lithium phosphite (LAP): 5 mg (the mass of LAP differs from that of PBS by more than two orders of magnitude, so the mass of LAP can be ignored);
[0141] ④ Use an analytical balance to weigh 5 mg of LAP and add it to a 15 ml centrifuge tube filled with PBS phosphate buffer. Adjust the oscillator to B mode (automatic mode) and set the speed to 800 rpm. Place the 15 ml centrifuge tube on the oscillator and oscillate for 5 minutes to obtain 10 ml of PBS phosphate buffer with a concentration of 0.05 wt% LAP. Wrap the centrifuge tube with tin foil and place it in a foam paper box containing an ice pack for later use (to prevent the photoinitiator from being inactivated by external light and temperature).
[0142] (II) Preparation of PBS solution containing PEG polymer and PBS solution containing MMP-9 specific peptide
[0143] ① Use an analytical balance to weigh 50 mg of 4-arm PEG-a-NB polymer powder and 7.93 mg of customized MMP-9 specific peptide powder, and place them in 2 ml semi-cylindrical bottom EP tubes respectively (keep the concentration of 4-arm PEG-a-NB polymer in the precursor solution at 10wt%, and keep the ratio of olefin bonds on the 4-arm PEG-a-NB polymer to thiol on the MMP-9 specific peptide at 1:1);
[0144] ② Use 100-1000μl and 10-100μl pipettes to draw 342μl of PBS phosphate buffer with a concentration of 0.05wt% LAP prepared in step 1 and add it to the EP tube containing 4-arm PEG-a-NB polymer powder and mix well;
[0145] ③ Use a 100-1000 μl pipette to draw 100 μl of the PBS phosphate buffer with a concentration of 0.05 wt% LAP prepared in step 1 and add it to the EP tube containing the customized MMP-9 specific polypeptide powder and mix well;
[0146] ④ Adjust the oscillator to B mode (automatic mode), set the speed to 800 rpm, place the two tubes of solution on the oscillator and oscillate for 5 minutes to obtain a PBS solution containing a 4-arm PEG-a-NB polymer and a PBS solution containing an MMP-9 specific polypeptide.
[0147] (III) Preparation of MMP-9 enzyme-responsive hydrogel precursor solution
[0148] ① Use a 100-1000 μl pipette to pipette the PBS solution containing the 4-arm PEG-a-NB polymer prepared in step 2 into the semi-cylindrical bottom EP tube containing the PBS solution of the MMP-9 specific polypeptide and mix well;
[0149] ② Adjust the oscillator to B mode (automatic mode), set the speed to 800 rpm, place the EP tube on the oscillator and oscillate for 5 minutes to obtain 442 μl of MMP-9 enzyme-responsive hydrogel precursor solution.
[0150] (IV) UV light curing of MMP-9 enzyme responsive hydrogel precursor solution and preservation
[0151] ① Use a 365nm ultraviolet lamp to irradiate the MMP-9 enzyme-responsive hydrogel precursor solution at a distance of about 1cm for 30 seconds to photocurate the MMP-9 enzyme-responsive empty hydrogel;
[0152] ② Place the solidified MMP-9 enzyme-responsive empty hydrogel in a drying container and store at low temperature.
[0153] 2.4 Experimental Results
[0154] like Figure 2 As shown, the hydrogel precursor can quickly change from liquid to gel after UV light curing for 30 seconds, which is in line with experimental expectations.
[0155] Figure 2 Successful preparation of hydrogel matrix;
[0156] 3. Drug loading and performance testing
[0157] 3.1 Composite particle size test
[0158] from Figure 2 It can be seen that the PNS-Tan composite particles are positively distributed. In a smaller particle size range, the volume density is higher, and the small-size particles occupy the main volume, which is conducive to the composite particles entering the internal network structure of the hydrogel to complete drug loading. The distribution range is narrow, and the average particle size is 32.337 μm.
[0159] 3.2 Hydrogel appearance, cross-linking degree and internal structure
[0160] The same cross-linking procedure was applied to the hydrogel loaded with PNS-TanⅡA, and PNS-TanⅡA was dissolved in the gel precursor solution, and the PNS-TanⅡA: gel precursor solution was ensured to be 1 mg: 100 μl. Figure 3 As shown, the gel prepared in this experiment is colorless, transparent, and crystalline, which is a classic gel morphology.
[0161] 3.3 Infrared spectroscopy analysis
[0162] like Figure 4 As shown, the hydrogel prepared in this application has a lower out-of-plane bending vibration of olefin CH (1000-675cm -1 ) and in-plane bending vibration (1430-1290cm -1 ) is significantly weakened, and the C=C characteristic stretch (1680-1640cm -1 ) disappeared, which is consistent with the theory that the gel network is formed through double bond reaction, and the gel cross-linking is successful.
[0163] 3.4 Scanning electron microscope test
[0164] like Figure 5 As shown, the hydrogel in the present application has a porous and interconnected microstructure, and its morphology is similar to that of the regenerative extracellular matrix.
[0165] 3.5 Rheological properties study
[0166] The dynamics of the transition from sol to gel of hydrogel was studied by rheological method. The change of storage modulus (G') and loss modulus (G") with time was studied by dynamic scanning. The time scanning curve of the obtained gel is shown in Figure 6 As shown. The results show that during the entire test stage, G' is higher than G", indicating that the material is not completely in a sol state; then G' increases, indicating that gelation begins; tanδ decreases with time, and the elasticity of the hydrogel increases during the gelation process. High storage modulus (G'), loss tangent (tanδ) and loss modulus (G") indicate that it has a stable network structure, strong elasticity and certain viscosity.
[0167] 3.6 In vitro swelling test
[0168] The hydrogel was immersed in PBS to simulate the in vitro swelling process under physiological conditions. The swelling curves were as follows: Figure 7 (A) and (B). The gel swelled rapidly in the first 4 hours of the experiment, and the swelling rate of the gel increased slowly after 24 hours and stabilized after 48 hours, indicating that the gel material has reached a balanced swelling state. The swelling rate of the hydrogel in this application is 300%, which can adapt to the highly humid environment of the oral cavity.
[0169] Figure 2 Composite particle size test analysis chart;
[0170] Figure 3 Appearance of successfully prepared hydrogel matrix;
[0171] Figure 4 Infrared spectrum of hydrogel;
[0172] Figure 5 SEM images of hydrogels;
[0173] Figure 6 Rheological properties of hydrogels;
[0174] Figure 7 Hydrogel swelling performance diagram;
[0175] Figure 8 Flow chart of the preparation of PNS-TanⅡA loaded hydrogel;
[0176] Fig. 9 Schematic diagram of hydrogel controlled drug release;
[0177] Fig.10 Schematic diagram of hydrogel network cross-linking.
[0178] Comparative Example:
[0179] Replace the therapeutic drug with single-ingredient drug of Panax notoginseng total saponins or tanshinone ⅡA.
[0180] 1. Compared with the use of TanⅡA alone, the embodiment adopts the solvent deposition method to improve the solubility of TanⅡA, so as to achieve the simultaneous release of fat-soluble TanⅡA and water-soluble PNS during the drug release process, thereby improving the solubility of TanⅡA.
[0181] 2. Compared with the use of PNS alone, the embodiment combines two anti-OSF Chinese medicinal ingredients, PNS and TanⅡA, in an orderly manner, while retaining the blood circulation and blood stasis effects of PNS and the antioxidant effects of TanⅡA, and exerting a synergistic therapeutic effect to further improve the efficacy.
[0182] Summary and discussion:
[0183] 1. New choice of therapeutic drugs: The preliminary experiments of this application verified the excellent therapeutic effects of Panax notoginseng total saponins and Salvia miltiorrhiza on oral submucous fibrosis, and then explored the possibility of combining the two drugs to treat OSF.
[0184] 2. Modification of drug composite particles:
[0185] The system of simple mechanical mixing of Tanshinone ⅡA particles and Panax notoginseng total saponin particles will result in uneven drug distribution, which significantly reduces the synergistic therapeutic effect of the two drugs. Therefore, we can make the drug particles evenly distributed through freeze drying, stabilize the system properties, and thus play a good synergistic role. The advantages of freeze drying over spray drying are: little effect on drug activity, high yield, simple operation, high safety, and long drying time.
[0186] In addition, unlike medicines composed of a single main ingredient, the effective substances of traditional Chinese medicine are diverse and holistic, and are mainly composed of two types of components: water-soluble and fat-soluble. Tanshinone ⅡA is slightly soluble in water and has strong fat solubility, while PNS is easily soluble in water and has strong water solubility. Due to the difference in solubility, these two types of components cannot be released simultaneously during the drug release process, thereby blocking the generation of synergistic effects and affecting the efficacy of the composite particles. After being modified with a hydrophilic matrix (solvent) - starch, the water solubility of Tanshinone ⅡA is greatly improved, the surface area is increased, the dissolution rate is accelerated, and the solubility is improved, realizing the orderly combination of the two traditional Chinese medicine components.
[0187] 3. Innovation of drug dosage forms:
[0188] Conventional treatment for OSF has a long course of treatment, high cost and inconvenient administration. This application uses drug-loaded hydrogel to innovate the oral submucosal fibrosis administration form, which is economical, efficient and convenient.
[0189] At present, the treatment of OSF is mainly drug therapy, supplemented by physical therapy. Drug therapy is mostly oral, topical application, local injection and other methods. These methods have limitations such as short drug retention time on the wound surface, difficulty in maintaining local concentration, and patient discomfort. This application uses click chemistry to construct a specific hydrogel network and uses hydrogel MMP-9 specific peptides to achieve intelligent responsive drug delivery; at the same time, MMP-9 is abnormally expressed in multiple organ fibrosis diseases, so this hydrogel construction scheme is also expected to provide new ideas for the treatment of other organ fibrosis.
[0190] The innovative drug delivery method of drug-loaded hydrogel is applied to the oral mucosa. The hydrogel as a carrier has the advantages of good adsorption and promotion of wound healing. It can prolong the drug controlled release time. Its good adsorption can tightly seal the wound, maintain local drug concentration for sustained release and promote wound healing, and it has little foreign body sensation.
[0191] The composite hydrogel described in the present invention is a multi-arm polyethylene glycol skeleton / MMP-9 specific polypeptide composite hydrogel loaded with drug PNS-TanⅡA. This innovative addition of traditional Chinese medicine composite particles PNS-TanⅡA to the multi-arm polyethylene glycol skeleton / MMP-9 specific polypeptide composite hydrogel has the potential to promote oral mucosal repair. In the present invention, the hydrogel described in the present invention is directly applied to the lesion site of oral submucosal fibrosis. Through the combined action of the various components in the hydrogel, OSF can be prevented from deteriorating into oral cancer, achieving a preventive and therapeutic effect.
[0192] The present invention provides a novel drug-loaded hydrogel for treating oral submucous fibrosis, and a preparation method and application thereof. The present invention synthesizes a PNS-TanⅡA drug-loaded hydrogel with good therapeutic effect. By combining the advantages of multiple materials, the novel hydrogel is expected to provide new drugs and dosage forms for treating oral submucous fibrosis, and has great clinical application potential. At the same time, the novel drug-loaded hydrogel is also expected to provide a new direction for the design of drug delivery systems for other mucosal diseases.
[0193] Glossary of relevant technical terms.
[0194] Oral submucous fibrosis (OSF): It is a precancerous state of oral cancer. It is a chronic, insidious, potentially malignant lesion that can affect any part of the oral cavity, sometimes even in the pharynx, and occasionally accompanied by soft palate blisters; pathological manifestations include atrophy of mucosal epithelial tissue, vascular occlusion, and changes in collagen fibers in the mucosal lamina propria and submucosal layer; clinically, it is characterized by oral pain when patients eat irritating foods, pale and stiff oral mucosa, and progressive mouth opening restriction and difficulty eating in severe cases, which further leads to problems with oral hygiene, speech, chewing and swallowing, and even psychological aspects of the patient.
[0195] Panax notoginseng saponins (PNS): It is the main active ingredient of Panax notoginseng, a plant of the genus Panax in the Araliaceae family. It contains a variety of monomeric saponins. It has pharmacological effects such as vasodilation, reduction of myocardial oxygen consumption, inhibition of platelet aggregation, anti-inflammatory and antioxidant effects. Panax notoginseng saponins are excellent anti-fibrotic agents and are widely used in heart, liver, lung and kidney fibrosis.
[0196] Tanshinone ⅡA (TanⅡA): extracted from the dried root of the Lamiaceae plant Salvia miltiorrhiza, cherry red needle-shaped crystals, insoluble or slightly soluble in water, easily soluble in organic solvents such as dimethyl sulfoxide, ethanol, acetone, ether and benzene. It can be used to prepare dripping pills, capsules, tablets, etc., and is clinically used for the treatment of coronary heart disease, angina pectoris, and myocardial infarction. Modern pharmacological studies have shown that tanshinone can induce apoptosis of fibroblasts and accelerate the decomposition and absorption of collagen fibers, thereby playing an anti-fibrosis role.
[0197] The compound Danshen dripping pills made from it can effectively inhibit the release of inflammatory mediators in the oral mucosa and have been used preliminarily in clinical practice. Usage: 1 mL of triamcinolone acetonide injection is injected into the base of the mucosal lesion area, once a week; compound Danshen dripping pills are taken orally, 10 pills each time, twice a day. The total treatment period is 3 months.
[0198] Matrix metalloproteinases (MMPs): Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) play an important role in the process of fibrosis. MMPs are a highly conserved family of hydrolases that can degrade ECM that appeared in the process of evolution in nature. Their activity is dependent on metal ions such as zinc ions and copper ions. MMPPS are mainly secreted in the form of zymogens. Under normal circumstances, they are not expressed or expressed at a low level. Only when stimulated by factors such as trauma and when tissues are repaired, their expression will be enhanced, promoting the degradation of the extracellular matrix. MMPs have been used by a large number of scholars to study the pathogenesis of fibrotic diseases. Among them, MMP-1, MMP-2, and MMP-9 are the most studied in relation to oral submucosal fibrosis.
[0199] Lithium phenyl-2,4,6-trimethylbenzoyl phosphite (LAP): Photoinitiator lithium phenyl-2,4,6-trimethylbenzoyl phosphite (LAP, purchased from Guangzhou Kerong Co., Ltd.) is a new type of water-based UV photoinitiator used to initiate water-based UV polymerization reactions of unsaturated prepolymer systems, especially suitable for water-based acrylate and unsaturated polyester resins.
[0200] In addition, it should be understood that although the present specification is described according to implementation modes, not every implementation mode contains only one independent technical solution. This description of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment may also be appropriately combined to form other implementation modes that can be understood by those skilled in the art.
Claims
1. A method for preparing a hydrogel for treating oral submucous fibrosis, characterized in that: The following steps are involved: S1 Preparation of Panax notoginseng total saponins-tanshinone ⅡA aqueous solution: S1.1 Modification of Tanshinone ⅡA by solvent deposition method: S1.1.1 Dissolve 0.2 g of Tanshinone ⅡA powder in 20 ml of anhydrous ethanol; S1.1.2 Disperse 2 g of pregelatinized starch into the solution and stir at a constant speed in a water bath at 40-50°C until the solution is completely evaporated; S1.1.3 Place the product in a constant temperature drying oven and dry it to constant weight; S1.1.4 Grind the material until it can all pass through an 80-mesh sieve to obtain tanshinone ⅡA modified particles; S1.1.5 Cover with tin foil and seal in a refrigerator for later use, and keep away from light; S1.2 Preparation of freeze-dried precursor solution: Dissolve 1 g of Panax notoginseng total saponins and the above-mentioned tanshinone ⅡA modified particles in a small beaker with ultrapure water to prepare a lyophilized precursor solution; S2 Pretreatment of freeze-dried samples, freezing stage: S2.1 Pour the freeze-dried precursor solution into the tray, the solution height is about 1mm; S2.2 Use sealing film to seal the opening of the pallet; S2.3 Place the tray containing the lyophilized precursor solution into an ultra-low temperature freezer at -80°C for 4 to 12 hours; Use of S3 Freeze Dryer, Sublimation Drying Stage: S3.1 Turn on the power of the drying chamber and wait for 20-30 minutes until the temperature indicator reaches -40℃ before starting the operation; S3.2 Take out the sample obtained in S2 from the ultra-low temperature freezer and use a sharp object to poke a small hole in the sealing film; S3.3 Place it in the drying chamber and close the valve connecting the drying chamber to the atmosphere to ensure good air tightness; S3.4 First check the oil level of the vacuum pump, connect the power supply after confirming that it is normal, then open the valve behind the drying chamber to connect it with the vacuum pump, and finally start the vacuum pump, wait for 20-30 minutes, observe the changes of the sample, and after confirming that there is no bumping phenomenon, continue to fully dry in the drying chamber for 12 hours; S4 Dehydration and storage of dried samples, dehydration stage: S4.1 Close the valve connected to the vacuum pump at the back of the drying chamber, turn off the vacuum pump, and unplug the power supply of the vacuum pump; S4.2 Loosen the air valve to restore the air pressure in the drying chamber to the same as the atmospheric pressure; S4.3 Turn off the power to the freezer compartment, unplug the power socket, and remove the plexiglass cover; S4.4 After taking out the dried sample, quickly cover it with a layer of sealing film and tie it tightly with a thin thread; S4.5 Clean and organize the equipment; S5 Preparation of PBS solution containing photoinitiator LAP: S5.1 Place a 15 ml beaker on an electronic scale, place a 15 ml centrifuge tube in the beaker, and zero the electronic scale; S5.2 Use a 100-1000 μl pipette to draw 10 ml of PBS phosphate buffer into a 15 ml centrifuge tube. The density of PBS phosphate buffer is 1 g / ml, and the electronic scale reading is 10 g. S5.3 Calculate the amount of LAP required to prepare 10 ml of PBS phosphate buffer with a concentration of 0.05 wt% LAP: 5 mg; S5.4 Weigh 5 mg of LAP using an analytical balance and add it to a 15 ml centrifuge tube filled with PBS phosphate buffer. Set the oscillator to automatic mode and set the speed to 800 rpm. Place the 15 ml centrifuge tube on the oscillator and oscillate for 5 minutes to obtain 10 ml of PBS phosphate buffer with a concentration of 0.05 wt% LAP. Wrap the centrifuge tube with tin foil and place it in a foam paper box containing an ice pack for later use. S6: Prepare PBS solution containing PEG polymer and PBS solution containing MMP-9 specific peptide: S6.1 Use an analytical balance to weigh 50 mg of 4-arm-PEG-NB polymer powder and 7.93 mg of customized MMP-9 specific peptide powder, and place them in 1.5 ml semi-cylindrical bottom EP tubes respectively, keeping the concentration of 4-arm PEG-a-NB polymer in the precursor solution at 10 wtwt%, and keeping the ratio of olefin bonds on the 4-arm PEG-a-NB polymer to thiol on the MMP-9 specific peptide at 1:1; S6.2 Use a 100-1000 μl and 10-100 μl pipette to draw 342 μl of the PBS phosphate buffer with a concentration of 0.05 wt% LAP prepared in step 1 and add it to the EP tube containing the 4-arm PEG-a-NB polymer powder and mix well; S6.3 Use a 100-1000 μl pipette to draw 100 μl of the PBS phosphate buffer with a concentration of 0.05 wt% LAP prepared in step 1 and add it to the EP tube containing the customized MMP-9 specific polypeptide powder and mix well; S6.4 Adjust the oscillator to the automatic mode and set the speed to 800 rpm. Place the two tubes of solution on the oscillator and oscillate for 5 minutes to obtain a PBS solution containing a 4-arm PEG-a-NB polymer and a PBS solution containing a MMP-9 specific polypeptide. S7 Preparation of MMP-9 enzyme responsive hydrogel precursor solution: S7.1 Use a 100-1000 μl pipette to pipette the PBS solution containing the 4-arm PEG-a-NB polymer prepared in step 2 into the semi-cylindrical bottom EP tube containing the PBS solution of the MMP-9 specific polypeptide and mix well; S7.
2. Adjust the oscillator to the automatic mode, set the speed to 800 rpm, place the EP tube on the oscillator and oscillate for 5 minutes to obtain 442 μl of MMP-9 enzyme-responsive hydrogel precursor solution; S8 Preparation of drug-loaded hydrogel precursor solution: S8.1 Dissolve PNS-TanⅡA in gel precursor solution, and ensure that the ratio of PNS-TanⅡA: gel precursor solution is 1 mg: 100 μl; S9 UV light curing MMP-9 enzyme response hydrogel precursor solution, storage: S9.1 Use a 365 nm ultraviolet lamp to irradiate the MMP-9 enzyme-responsive hydrogel precursor solution at a distance of 1 cm for 30 seconds to photocurate the MMP-9 enzyme-responsive drug-loaded hydrogel; S9.2 Place the solidified MMP-9 enzyme-responsive drug-loaded hydrogel in a drying container for low-temperature storage.
2. A hydrogel for treating oral submucous fibrosis, characterized in that: The hydrogel for treating oral submucosal fibrosis is prepared by the method for preparing the hydrogel according to claim 1, and the hydrogel has the following performance characteristics: ① Hydrogel appearance: colorless and transparent, crystalline and frozen, a classic gel form; ② Infrared spectroscopy characterization of hydrogel: Compared with four-arm PEG-a-NB, the out-of-plane bending vibration of olefin CH is 1000-675cm -1 and in-plane bending vibration 1430-1290cm -1 Significantly weakened, C=C characteristic stretch 1680-1640cm -1 disappear, a gel network is formed through double bond reaction, and the gel is successfully cross-linked; ③Scanning electron microscopy characterization of hydrogel: The hydrogel has a porous and interconnected microstructure, and its morphology is similar to that of regenerated extracellular matrix; ④ Rheological properties: hydrogel has a stable network structure, strong elasticity and certain viscosity; ⑤ In vitro swelling performance: The equilibrium swelling rate of the hydrogel is 300%, which is suitable for the highly humid environment of the oral cavity.
3. The use of a hydrogel for treating oral submucous fibrosis according to claim 2, characterized in that: Used for preparing a pharmaceutical composition for treating oral submucous fibrosis.
